Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Domestic market and developing countries will need doses of Indian vaccines
The project is a collaboration between IIT Delhi and AIIMS
The hospital chain aggressively embarks on digitisation and is e-health ready
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
